News
Article
Author(s):
The feature will be available on the company’s platform Nuro.
Access Infinity announced a new AI-powered solution.
Stock.adobe.com
Access Infinity launched a new AI-powered price and health technology assessments (HTA) for its market access insights platform Nuro. According to the company, this feature can reduce drug pricing and HTA outcome analysis done to minutes. The feature can also produce “actionable insights” for the platform’s users.
In a press release, Access Infinity’s product owner Tom Gilboy said, “In the last 12 months in particular, we’ve seen many Market Access teams make the leap from exploring how they can adopt AI to embracing AI by integrating it into their everyday processes.”
Gilboy also said, “This latest development on Nuro allows Early Market Access leaders and their teams to take the next step. The feature provides a solid foundation for business development and asset assessments, giving users more strategic thinking time to focus on optimizing the asset itself, rather than conducting the initial estimate."
Keshav Nagaraja, digital managing director, added, “Our deep understanding of market access challenges, combined with innovative AI capabilities, allows us to deliver solutions that truly move the needle for our clients.”
This is the latest AI-powered solution offered by Access Infinity. In March of this year, the company launched a tool designed to help navigate the EU’s Joint Clinical Assessment (JCA) framework. JCA Navigator uses AI to provide solutions for clinical evaluations, streamlining evidence generation, and optimizing market access strategies.
In a press release issued at the time, Nagaraja said, “The JCA framework aims to standardize clinical assessments across EU member states, reducing duplication and increasing efficiency. Although it presents new challenges, adopting the right tools can also create opportunities for greater consistency and efficiency in evidence generation across EU markets. Access Infinity’s JCA Navigator tool provides the predictive insights and automation capabilities necessary to simplify assessments, reduce uncertainty, and enhance strategic planning.”
In November of last year, Access Infinity announced Evidence Hub, another AI-powered management solution, this designed for use by cross-functional teams dealing with disparate and static repositories of evidence.
At the time, Nagaraja said of Evidence Hub, “Scattered evidence has become a huge challenge for HEOR, value, and access teams. Many of the teams we engage with struggle to keep track of evidence because it's stored in disparate locations such as SharePoint folders, Excel, and other systems - relying on individual team members to know where and how to find it. This outdated approach leads to inefficiencies, problems with version control, data governance and potential loss of information. It also causes delays in sharing critical insights across multifunctional teams, especially during preparation for and execution of HTA, pricing, and reimbursement negotiations during launch. Evidence Hub addresses these challenges and saves hours of manual effort by providing a structured, centrally hosted repository with built-in governance. It provides a living library with intuitive filters and AI-powered features which empowers teams to seamlessly manage all the latest publications and evidence in one place.”
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.